Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 07/27/2011) - New results from the NCI-sponsored Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial show that screening for ovarian cancer with transvaginal ultrasound (TVU) and the CA-125 blood test did not result in fewer deaths from the disease compared with usual care.
NIH-funded study shows reduction in death for men with intermediate-grade prostate cancer:
(Posted: 07/13/2011) - Short-term hormone therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared to treatment with radiation therapy alone, according to a clinical trial supported by NCI. Benefits of the combined treatment were limited mainly to patients with intermediate-risk disease and were not seen for men with low-risk prostate cancer, researchers say.
Colorectal Cancer Trials Support Gene Testing for Two Drugs
(Posted: 11/12/2008, Updated: 07/08/2011) - A trio of 2008 studies adds to the growing evidence that patients with colorectal cancer should have their tumors tested for genetic mutations prior to starting therapy with cetuximab (Erbitux®) or panitumumab (Vectibix®).
NIH-funded study shows 20 percent reduction in lung cancer mortality with low-dose CT compared to chest X-ray:
(Posted: 06/29/2011) - Scientists have found a 20 percent reduction in deaths from lung cancer among current or former heavy smokers who were screened with low-dose helical computed tomography (CT) versus those screened by chest X-ray.
Tool Weighs Benefits, Risks of Raloxifene or Tamoxifen to Prevent Breast Cancer
(Posted: 06/14/2011) - Researchers have developed a benefit-risk index to help guide decisions on whether postmenopausal women at increased risk of developing breast cancer should take raloxifene or tamoxifen to reduce that risk.